National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 1) (Cth)
PB 9 of 2022
National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 1)
I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following Determination.
Dated 27 January 2022
NIKOLAI TSYGANOV
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
1 Name........................................................................................................................................ 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Schedules................................................................................................................................. 1
Schedule 1—Amendments 2
National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021) 2
1 Name
This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 1).
This instrument may also be cited as PB 9 of 2022.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 February 2022. | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under section 85B of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021)
1 Schedule 1, entry for Enalapril in the form Tablet containing enalapril maleate 10 mg
omit from the column headed “Claimed Price”: 8.83 substitute: 12.55
2 Schedule 1, entry for Enalapril in the form Tablet containing enalapril maleate 20 mg
omit from the column headed “Claimed Price”: 9.60 substitute: 13.32
3 Schedule 1, entry for Hypromellose
(a)omit from the column headed “Determined Price”: 2.08 substitute: 1.74
(b)omit from the column headed “Claimed Price”: 6.12 substitute: 5.12
4 Schedule 1, entry for Levothyroxine in the form Tablet containing 50 micrograms anhydrous levothyroxine sodium
(c)omit from the column headed “Determined Price”: 13.71 substitute: 10.28
(d)omit from the column headed “Claimed Price”: 15.49 substitute: 11.62
5 Schedule 1, entry for Levothyroxine in the form Tablet containing 75 micrograms anhydrous levothyroxine sodium
(e)omit from the column headed “Determined Price”: 14.23 substitute: 10.67
(f)omit from the column headed “Claimed Price”: 16.07 substitute: 12.05
6 Schedule 1, entry for Levothyroxine in the form Tablet containing 100 micrograms anhydrous levothyroxine sodium
(g)omit from the column headed “Determined Price”: 14.20 substitute: 10.65
(h)omit from the column headed “Claimed Price”: 15.99 substitute: 11.99
7 Schedule 1, entry for Levothyroxine in the form Tablet containing 200 micrograms anhydrous levothyroxine sodium
(i)omit from the column headed “Determined Price”: 16.65 substitute: 12.49
(j)omit from the column headed “Claimed Price”: 18.44 substitute: 13.83
8 Schedule 1, entry for Mirtazapine
omit from the column headed “Claimed Price”: 8.00 substitute: 8.94
9 Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg
omit from the column headed “Claimed Price”: 11.05 substitute: 12.83
10 Schedule 1, entry for Piroxicam
Omit
| Piroxicam | Capsule 20 mg | Oral | Feldene | 25 | 4.45 | 11.89 |
| Dispersible tablet 20 mg | Oral | Feldene D | 25 | 4.45 | 11.89 |
Substitute
| Piroxicam | Dispersible tablet 20 mg | Oral | Feldene D | 25 | 4.45 | 11.89 |
11 Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Brand: Lipex 20]
omit from the column headed “Claimed Price”: 8.48 substitute: 10.16
12 Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Brand: Zocor]
omit from the column headed “Claimed Price”: 8.48 substitute: 10.77
13 Schedule 1, entry for Simvastatin in the form Tablet 40 mg [Brands: Lipex 40; Zocor]
omit from the column headed “Claimed Price”: 9.14 substitute: 10.77
0
0
0